Objective: To test the effectiveness of glucosamine (GluNH 2 )-HCl, chondroitin sulfate (CS) and mixtures in protecting cartilage exposed to fibronectin fragments (Fn-fs), an exposure known to enhance catabolic cytokines and matrix metalloproteinases (MMPs).
Introduction
Glucosamine (GluNH 2 ) and chondroitin sulfate (CS) are two commonly used nutraceutical compounds that have been reported to have chondroprotective qualities. GluNH 2 is an amino monosaccharide precursor that is incorporated, either directly or after conversion to galactosamine, into the disaccharide unit of glycosaminoglycans (GAGs) found in proteoglycans (PGs) in the cartilage matrix. CS is a longchain, sulfated polymer of up to 40-kDa of repeating, partially sulfated disaccharide units of galactosamine sulfate and glucuronic acid and represents the majority of GAGs in articular cartilage 1 .
Clinical trials on GluNH 2 used in relief of osteoarthritis (OA) symptoms have shown that GluNH 2 has a moderate treatment effect, whereas CS has a larger treatment effect 2e4 . Although slower acting than nonsteroidal antiinflammatory drugs (NSAIDs), GluNH 2 has been reported to be as effective as NSAIDs at relieving the symptoms of OA 5, 6 . Efficacy depends on the measurement methodology, with the Lequesne Index showing improvement over placebo in many studies but no improvement when the WOMAC Index is used 7e9 . Some studies have shown no effect, possibly related to the source of GluNH 2 used 7e9 as discussed 10 . CS has also been shown to be efficacious for the treatment of mild to moderate OA 11e13 and also as effective as NSAIDs in pain reduction 11 . Several studies also indicated a disease modification potential in knees and hands 12, 13 .
Although CS and GluNH 2 are now commonly used as a combination for treatment of OA, only a few studies have evaluated efficacy of the combination. Das and Hammad 14 conducted a randomized, placebo-controlled study with 93 knee OA patients, using as the primary outcome the Lequesne Index of Severity of OA of the Knee (ISK) and found that the combination with added manganese ascorbate showed significant improvement over the placebo 14 . In a smaller study of subjects with degenerative joint disease of the knee or lower back, Leffler et al. 15 used the same combination and showed significant effects over placebo on patient assessment of treatment effect, visual analog scale for pain, and physical examination score. A large, ongoing study (the Glucosamineechondroitin Arthritis Intervention Trial, ''GAIT'') 16 is currently comparing CS and GluNH 2 hydrochloride, alone and in combination, to a nonsteroidal cyclooxygenase-2 inhibitory drug (NSAID) using the same source of CS used in these two smaller studies 14, 15 . To date, this study, which is using the WOMAC Index, has shown that the combination is substantially more effective than either agent alone in relieving symptoms of knee OA, even surpassing the NSAID in effectiveness 16 . Interestingly, only those patients with moderate to severe knee pain had a better response with the combination than with celecoxib. It remains to be seen whether or not these results will be evident in a larger set of patients.
The specific combination of GluNH 2 hydrochloride and low molecular weight CS, with added manganese ascorbate, has also been studied clinically in animals and with in vitro studies. The mixture has been shown in vitro to act synergistically in stimulating the production of PGs in the articular cartilage, while inhibiting the activity of the degradative enzymes that act on articular cartilage 17 . In a study of surgical reconstruction of canine cruciate ligament, this formulation taken orally, stimulated cartilage metabolism as measured by an increase in CS epitopes 3B3 and 7D4 18 . Animal trials have also shown this combination to exert a protective effect on cartilage degradation in various experimental models 17e20 .
While the clinical effectiveness of GluNH 2 and CS is controversial and warrants further studies, the possible mechanism(s) of action also remain a matter of controversy and ongoing research. Reported in vitro effects of GluNH 2 include stimulation of GAG synthesis 21, 22 , inhibition of cyclooxygenase independent anti-inflammatory properties 23, 24 and inhibition of IL-1 stimulated gene expression 25e31 or protease activity 32 . Reported effects of CS include stimulation of synthesis of PG 12, 13, 17, 33 , inhibition of degradative enzymes 34e36 and inhibition of IL-1 stimulated gene expression and production of pro-inflammatory genes including matrix metalloproteinases (MMPs) 28, 29, 32 . Thus, each agent has been reported to have both proanabolic and anti-catabolic or anti-inflammatory activities.
One complication in interpretation of relevant published studies is that many of these studies have used concentrations of CS and GluNH 2 far higher than the levels reported to occur after oral ingestion. Typical concentrations of the agents in plasma after oral ingestion are in the tens of mg/ml. For example, pharmacokinetic studies indicate a bioavailability of CS up to 5e70%, with some of the CS being absorbed as partially degraded components 37 and maximal concentrations of 3e36 mg/ml, depending on the species 17,38e41 . In contrast, GluNH 2 in plasma has very low bioavailability, due to the apparent effect of first pass metabolism 38,42e45 . Radiotracer studies show high uptake 23,24,38,42e45 and maximal levels of unmetabolized GluNH 2 in dogs, horses, and humans of 2e11 mg/ml 38,42e45 . These levels are far below those often used for in vitro studies and apparently too low to serve as an effective, glucose-competing substrate for PG synthesis 23,24,38,42e47 . These results draw into question the assumption that GluNH 2 and/or CS act by providing additional substrates for PG synthesis. However, it should also be noted that CS given in a low mass form has been shown, like GluNH 2 , to have an affinity for articular cartilage 36 and thus, serum levels of these agents may not be useful in predicting their efficacy after oral ingestion. Nonetheless, only recently have studies on GluNH 2 shown effects on chondrocytes at low mg/ml concentrations, and only one study has shown clear effects of CS on inhibition of IL-1 action at the reported physiological concentration 28, 29, 31 . There have also been limited studies that have tested whether specific combinations are more effective than the individual agents 17 , although it has been postulated that combining GluNH 2 with CS yields a synergistic rather than additive effect 48, 49 .
In order to investigate whether or not GluNH 2 and CS as single agents or as a combination at concentrations close to those observed after oral ingestion are effective, we have tested the GluNH 2 hydrochloride and the CS used in the GAIT study 16 and also tested in other studies 16, 17, 28, 29 , in a cartilage chondrolytic culture model in which the catabolic mediators, fibronectin fragments (Fn-fs), are added to cartilage explants 50 . The Fn-fs elevate catabolic cytokines 51, 52 and MMPs 51, 53 which cause transient suppression of PG synthesis and severe depletion of cartilage PG 54 . Since the damaged bovine cartilage does not spontaneously restore PG after the Fn-fs are removed, this model is also useful for tests of effects on cartilage repair (reviewed in Ref. 55) . The relevance of this model is based on our observations that Fn-fs are found in OA synovial fluids and cartilage, that injection of Fn-f into rabbit knee joints causes cartilage degeneration 56, 57 and that these Fn-fs are easily generated under cartilage damage conditions initiated by other catabolic mediators such as addition of MMP-3 or IL-1 to cultured cartilage 58 . MN) . The GluNH 2 and CS pharmacologic formulations tested (GluNH 2 hydrochloride (FCHG49 Ò ) and CS (TRH122 Ò )) were from Nutramax Laboratories, Inc. (Edgewood, MD). Solutions were made up fresh at the start of the experiment and kept frozen for up to 21 days in between use.
Materials and methods

ISOLATION OF Fn-fs
An amino-terminal 29-kDa thrombin-generated Fn-f is the most characterized of the Fn-fs in terms of cartilage chondrolytic activities 55 . However, for these studies, a more physiologically relevant mixture of Fn-fs was the major type of Fn-f studied. The mixture was derived by digestion of human plasma fibronectin with 1 mg/ml MMP-3 and contains Fn-fs of 29-kDa, 40e60-kDa and 120e160-kDa, and has been described elsewhere 59 . This mixture has activities indistinguishable from the thrombin-generated 29-kDa. In comparisons between the two different types of Fn-fs, assays of the effects of the mixture on rates of PG degradation in bovine metacarpophalangeal cartilage in DMEM cultures showed 794 G. A. Homandberg et al.: Cartilage repair by GluNH2 and CS that a 1 mM solution of this mixture (500 mg/ml of total Fn-fs) had approximately the same rate constant as a 1 mM solution of the highly purified amino-terminal 29-kDa Fn-f. The mixture at 1 mM also suppressed PG synthesis to the same level as 1 mM 29-kDa Fn-f when assayed as described 54 .
In order to add credibility to our use of the mixture, we tested whether a 29-kDa band found in the mixture was similar to the thrombin-generated 29-kDa Fn-f. The MMP-3 digest mixture was subjected to electrophoresis on 10% acrylamide gels, lightly stained with Coomassie Blue in fresh plastic containers. Bands of 29-kDa, 50e70-kDa and 140e160-kDa were detected after light staining with Coomassie. The 29-kDa band was excised, subjected to trypsin digestion and peptides analyzed by ESI-QUAD-TOF mass spectrometry using standard protocols. The band yielded a tryptic fragment of residues 58e67. Therefore, the small 29-kDa Fn-f in the MMP-3 digest is likely the same thrombin-generated 29-kDa Fn-f we have extensively studied which contains residues 1e259.
In order to ensure that active proteinases in the Fn-f solutions did not account for cartilage degradation, their effects at 1 mM concentrations on cartilage in DMEM that had been freeze-thawed for three cycles to inactivate metabolic processes were measured. None of the Fn-fs solutions had a significant effect on enhancing PG degradation and release into the culture media over a 7 day period. Further, in order to ensure that no MMP-3 activity remained in the mixture, the MMP-3 digest was passed over reactive Reactive Red 120-agarose to remove MMP-3 and then subsequently treated with 10 mM ethylenediaminetetraacetic acid (EDTA), prior to a final dialysis against phosphate buffered saline (PBS). In order to ensure that trace inactive MMP-3 in the MMP-3 digest which may have not been totally removed by Reactive Red-agarose treatment would not interfere with our MMP blotting, the 29-kDa thrombingenerated Fn-f was utilized in experiments where media were to be blotted against anti-MMPs. All the Fn-f solutions were treated with detoxi-Gel prior to use, dialyzed to remove protease inhibitors and EDTA and sterile filtered. Assays of endotoxin with a kit from Sigma Chemical Co. showed levels <50 pg/mg of protein in any Fn-f solution.
EXPLANT CULTURES
Culturing of slices of bovine metacarpophalangeal cartilage from 18-month-old bovines was performed as described 54 in DMEM containing 50 U/ml penicillinestreptomycin in 10% serum/DMEM or in DMEM alone and with 20e60 mg cartilage per 1.5 ml/well. The cartilage was allowed to equilibrate for 2 days in DMEM alone prior to adjustment to the final culturing conditions. During the culture, the media were changed every other day for 10% serum/ DMEM cultures but were not changed for kinetic assays of PG degradation in serum-free cultures. Each condition was replicated in triplicate for each culture.
ASSAYS OF KINETICS OF PG DEGRADATION
The kinetics of PG degradation and release into the media in serum-free cultures were studied in order to generate conditions in which the damaged cartilage could not effectively respond with enhanced anabolic activities that might have been contributed by growth factors in serum. These conditions provide tests of the effects on mostly catabolic activities. Briefly, cartilage was preequilibrated in DMEM for 2 days and then adjusted to various concentrations of the agents or a mixture. For the mixture, the concentrations given refer to the concentration of each agent. After 4 h, the cultures were adjusted to 1 mM Fn-f. The media were not changed during the culture. Each day, for up to 5 days, 50 ml aliquots of the culture media were removed, the media diluted 10-fold and PG content was assayed using the dimethylmethylene blue (DMB) assay as modified 50 . The PG content was converted to mg PG/mg cartilage for each of three similar wells and the amounts graphed vs day in culture to determine rate constants of mg PG/mg cartilage/day by linear regression. Separate assays showed that CS when added to the PG standards used to generate our standard curve or added to papain digests did not increase the colorimetric response, indicating that CS that had been added to the media was not capable of interfering with the assay.
ASSAYS OF EFFECTS OF AGENTS ON PG CONTENT OF CARTILAGE IN 10% SERUM CULTURES
In order to test the effects of the agents on blocking Fn-f mediated PG degradation as measured by the PG content of cultured cartilage, conditions of 10% serum were used. These conditions are more physiologic than serum-free and are conditions in which damaged cartilage has serum growth factors in the media which would help mount an anabolic response to the damage as well as proteinase inhibitors which would decrease proteolytic damage. This latter culture system allowed us to measure effects of agents on homeostasis closer to steady state conditions than serum-free and thus, to measure the summation of anabolic and catabolic events. We have shown that in these longterm 21e28 day cultures, that cell viability as measured by DNA content does not decrease by more than 20%, an amount not statistically different than untreated cartilage 54 . Bovine cartilage was cultured in 10% serum/DMEM with the single agents or with a mixture and with or without 100 nM Fn-f for periods up to 21 or 28 days. For the mixture, the concentrations given refer to the concentration of each agent. The agents were added first, followed by addition of Fn-f 4 h later. Media were changed every other day. Every 7 days, the PG content of the remaining slices was measured by DMB assays of papain digests. Each condition was replicated in triplicate for each culture.
ASSAYS OF EFFECT OF AGENTS ON PG CONTENT OF DAMAGED CARTILAGE IN 10% SERUM CULTURES
In order to test the reparative activity of the agents, cartilage was damaged with 100 nM Fn-f prior to addition of agents. Briefly, bovine cartilage was cultured in 10% serum/DMEM with 100 nM Fn-f from days 0e7 to deplete PG. Media were changed every other day. At day 7, some of the cultures were adjusted to various concentrations of GluNH 2 and CS or mixtures but without Fn-f. For the mixtures, the concentrations given refer to the concentrations of each component. PG content was analyzed every 7 days. PG contents were determined on papain digests using the DMB assay as described 54 . The PG contents were reported as mg PG/mg wet weight cartilage. Each condition was replicated in triplicate for each culture.
WESTERN BLOTTING AND CHEMILUMINESCENT DETECTION OF MMPs
In order to test whether potentially beneficial effects of the agents might occur through the ability to suppress expression of MMPs, Western blotting of conditioned media was 795 Osteoarthritis and Cartilage Vol. 14, No. 8 employed. We have shown that MMP activity is involved in the ability of Fn-fs to decrease PG content of cultured cartilage 60 . An aliquot of conditioned serum-free media, after concentrating 10-fold, was applied to 7.5 or 10% acrylamide sodium dodecyl sulphate (SDS) gels run at 30 mA per gel and the resultant gels blotted onto nitrocellulose for 1 h at 100 V. The amount of protein applied in each lane was identical and typically about 5 mg, as measured with the modified Lowry protein assay. The blot was then treated with 3% BSA in 20 mM Tris buffer, pH 7.4, containing 140 mM NaCl (Tris buffered saline (TBS)) for 1 h at room temperature or overnight at 4(C. The blot was then incubated with a 1e5000 fold dilution of anti-MMP-3 or 1e3300 for anti-MMP-13 for 1 h, washed three times with TBS containing 0.1% Tween 20 (TBST) for 5e10 min each. The blot was then reacted with HRP conjugated rabbit anti-sheep IgG for 1 h, washed three times with TBST and one last time with TBS. The blot was then reacted with Supersignal West Dural Extended Duration substrate (Pierce Chemical Co., Rockford, IL) for 5 min before being placed in a plastic membrane protector. The image was captured by a Lumi-Imager with BoehringereMannheim Lumi Analyst 3.0 software.
When 10% serum conditioned media were concentrated 10-fold and subjected to blotting against anti-MMP-3, broad heavy smears of about 70-kDa in both nontreated and Fn-f treated samples, due to 100% serum, made visualization of MMP-3 bands difficult. As an alternative, a human MMP-3 ELISA kit was tested but no significant reaction was noted from any samples. As another alternative, media were first treated with Reactive Red 120-agarose to concentrate MMP-3 and separate it from the serum. A 50 ml suspension (50/50) of agarose was mixed with 1.0 ml of nonconcentrated conditioned media for 30 min, followed by washing of the resin with TBS and treatment of the resin with denaturation buffer and reducing agent. This yielded a releasate that when subjected to blotting yielded elevated MMP-3 bands in Fn-f treated cultures and only baseline levels in non-Fn-f treated cultures.
ASSAYS OF EFFECTS OF AGENTS ON PG SYNTHESIS IN EXPLANTS
In order to test whether potentially beneficial effects of the agents might occur through the ability to reverse the PG synthesis suppression activity of Fn-fs 54 , assays of 35-S sulfate incorporation were employed. Bovine cartilage was cultured in 10% serum/DMEM cultures in the presence of various concentrations of the agents alone or as a mixture. For the mixture, the concentrations given refer to the concentration of each agent. Four hours after addition of agent, some cultures were adjusted to 100 nM Fn-f. Media were changed every other day. At various times, the media were adjusted to 10 mCi/ml of 35 S-sodium sulfate for 2 h, followed by a 2-h cold chase with 10% serum/DMEM. Slices were weighed and then extracted with 1 ml of 4 M guanidine-HCl, 0.1% Triton X-100, 10 mM EDTA, 100 mM sodium acetate, pH 5.5 for 16 h, followed by exhaustive dialysis of the extracts against 10 mM EDTAewater. For explants, the amount of label was expressed as dpm/mg wet weight cartilage and converted into percentage of values for control untreated cultures. Each condition was replicated in triplicate for each culture.
STATISTICAL TREATMENT
For kinetic assays of PG degradation, three wells were used per time point in each culture and 5 days analyzed by linear regression to obtain rate constants and S.E.M. values. An n value of 15 was used to compare slopes using the two-tailed unpaired Student's t test. For assays of PG content and of PG synthesis rates, for each major culture, cartilage was pooled from three to four bovines and three culture wells were used for each condition. Each of the major cultures was performed four times 1 month apart and the final mean and final S.E.M. values from a total of 12 wells/datum were determined as n ¼ 12. In this way, the variance in the final analysis reflected as many parameters as possible, including but not limited to, cartilage weighing variation, assay variation, culturing condition variations and cartilage heterogeneity. Cartilage heterogeneity was inherent due to well to well variation in cartilage slice masses, shapes and original in situ joint locations, the latter of which could theoretically introduce variability in biochemical response. Once the final mean and S.E.M. values were calculated, control vs experimental data at selected time points were compared using two-tailed unpaired Student's t tests of the 12 culture wells and associated S.E.M. values. This analysis allowed us to perform pairwise analysis of single time points without assumption of a mechanism that would be implied by analysis of data as kinetic curves. In order to concisely describe statistical trends in a subset of data, P values, representing the least significance within the set are given where possible and appropriate.
Results
GluNH 2 OR CS SEPARATELY OR IN A MIXTURE DID NOT DECREASE KINETICS OF DAMAGE
In the first test of effects of the agents, serum-free conditions were chosen such that proteinase inhibitors and growth factors present in serum would not be able to contribute a response to the damage and obscure visualization of blocking of catabolism. Aliquots of media were removed each day to measure PG contents so rate constants could be estimated. Figure 1 shows that the Fn-f mixture (MMP-3 generated) enhanced the rate of PG degradation and release into the media as compared to untreated cartilage. Further, 100 mg/ml of either GluNH 2 or CS alone had no effect on the PG release kinetics. To test protective effects, the agents at 0.1e100 mg/ml singly or in mixtures (M) were added to cartilage, followed 4 h later by addition of the Fn-f mixture. The agents did not significantly decrease the enhanced rate caused by the Fn-f while a concentration of 100 mg/ml significantly increased the rate (P ¼ 0.002). Analysis of the PG remaining at the end of the experiments, confirmed that the agents did not significantly decrease the ability of Fn-fs to decrease PG content (data not shown).
Since the data in Fig. 1 suggested that the agents did not decrease PG catabolism, we investigated next whether this lack of blocking correlated with lack of effect on expression of a major MMP involved in Fn-f mediated cartilage damage, MMP-3 60 . Conditioned media from similar serum-free cultures as in These experiments were performed with three different cartilage preparations with similar observations. However, the agents paradoxically appeared to slow Fn-f mediated MMP-3 release (Fig. 3) . Each test of the agent corresponds to a well in which the 29-kDa Fn-f was added 4 h after test agent. The blots on the left side show that initially GluNH 2 and CS appeared to decrease Fn-f mediated MMP-3 release, although this blocking is mostly lost by day 3, although the levels are still lower at day 3 than in Fn-f treated controls. An anomaly is also observed, in that 1 and 10 mg/ml GluNH 2 seem to be more effective than the highest concentration. CS appeared to decrease MMP-3 in a dose dependent fashion. The panels on the right are for the mixture of the agents and show that the mixture was also ineffective by day 3 and appeared to be weaker than that of either of the single agents. Concentrations of 0.01 and 0.1 mg/ml were also tested and found not to decrease MMP-3 expression (data not shown). These experiments were performed with four different cartilage preparations with similar observations.
Since MMP-13 is also thought to be a critical MMP involved in physiological cartilage degradation, it was also probed. Figure 4 shows similar effects of GluNH 2 and CS at days 1 and 3 for MMP-13 compared to MMP-3. By day 3, there was little blocking of MMP-13 release. Thus, both MMPs were affected similarly by the treatments with maximal MMP release delayed until day 3. Most of the lanes for day 1 show both the higher molecular weight 60-kDa proMMP-13 form and the active 48-kDa form, while lanes for day 3, especially those for GluNH 2 and CS additions show only very low levels of proMMP-13, suggesting that activation of proMMP-13 is occurring with time in the cultures and that the agents do not block activation by day 3. In contrast, the mixture at day 3 appears to show some degree of blocking of activation.
Since blotting is semiquantitative, we did not attempt to compare amounts of any of the MMPs at day 3 with the Fn-f treated samples. The data shown do suggest that the agents are still partially effective in blocking at day 3. Nonetheless, as will be shown below the effects on MMP release when the agents are compared to the mixture did not correlate with the order of their effects on blocking damage or promoting restoration of PG. The previous observations suggested that the agents were not powerful enough to block catabolism under serum-free conditions in the absence of serum growth factors and proteinase inhibitors. We next tested whether the agents could block Fn-f mediated cartilage PG depletion in the presence of serum which would provide proteinase Four cartilage harvests were used for the analysis. 797 Osteoarthritis and Cartilage Vol. 14, No. 8 inhibitors to limit damage and anabolic growth factors to allow cartilage mediated compensation to the damage. In this serum culture system, the PG content of the remaining cartilage is measured and this reflects not only catabolism but the summation of catabolism and anabolism over a culture period of up to 21 days. Figure 5 (A) shows that when cartilage was adjusted to 1, 10 or 100 mg/ml GluNH 2 alone without Fn-fs, PG content was unaffected. The apparent decrease in PG content with 100 mg/ml of agent at days 14 and 21 was insignificant. However, when Fn-fs were added 4 h after addition of the agents, the 100 mg/ml concentration appeared to decrease Fn-f mediated PG loss by days 7, 14 and 21 (P < 0.01 for all) as compared to Fn-f treatment. A weaker protective effect was observed for 1 and 10 mg/ml at day 7 (P ¼ 0.01 for both) but only for 10 mg/ml at day 21 (P ¼ 0.007). Concentrations of 0.01 and 0.1 mg/ml were not tested because of the weaker effect of 1 mg/ml. Fig. 5(B) . In this case, CS alone at any concentration had no significant effect on PG content. However, CS at all concentrations appeared to diminish Fn-f mediated decreases in PG content by day 14 and by day 21 and there also appeared to be a repair response. When compared to Fn-f treatment, 1, 10 and 100 mg/ml decreased Fn-f activity, at day 7 (P ¼ 0.01, 0.06, and 0.005, respectively), at day 14 (P < 0.004) and at day 21 (P < 0.0004). Concentrations of 0.01 and 0.1 mg/ml did not have a significant effect (data not shown).
CS was tested in a similar fashion as shown in
In contrast, Fig. 5 (C) shows that mixtures of the agents at 0.1, 1, 10 and 100 mg/ml very effectively blocked Fn-f mediated PG depletion at day 7 (P ¼ 0.02, 0.01, 0.0005, and 0.0002, respectively). A concentration of 0.01 mg/ml was ineffective (data not shown). For day 14, concentrations of 1, 10 and 100 mg/ml were still effective (P < 0.005), as well as for day 21, (P < 0.001). Concentrations of 1 mg/ml (shown) and 0.01 mg/ml had no significant effect (data not shown). In the next type of experiment, cartilage was damaged first by culture with Fn-f for 7 days, in order to test for the ability of agents to enhance restoration of lost PG. The Fn-f was removed at 7 days and agents added. Figure 6 (A) shows that treatment of nondamaged cartilage with 10 or 100 mg/ml of GluNH 2 alone did not have a significant effect on decreasing PG content by day 14. However, by day 21, 10 mg/ml did decrease PG content by 11% with similar effects of 100 mg/ml (P < 0.0005 for both). At day 28, 10 and 100 mg/ml decreased PG content (P < 0.003 for both) as compared to untreated control. Apparently, GluNH 2 had a small but significant effect, by itself. Adjustment of Fnf damaged cartilage cultures to 100 mg/ml GluNH 2 at day 7, did not significantly increase PG content by day 14 or 21, as compared with Fn-f treatment but did so by day 28 (P ¼ 0.005). However, concentrations of 1 or 10 mg/ml had no significant effect at any time points. Concentrations of 0.01 and 0.1 mg/ml were not tested because of the weaker effect of 1 mg/ml. Figure 6 (B) shows that CS alone, when added to nondamaged cartilage, had no significant effect on PG content at any time points. Further, adjustment of Fn-f damaged figure) (panel C) also in presence or absence of 100 nM MMP-3 generated Fn-f. The mixture was also tested at 0.1 mg/ml. PG content was measured every 7 days. The curves corresponding to agent alone, in the absence of Fn-f, generally followed the linear horizontal profile for the nontreated control. 799 Osteoarthritis and Cartilage Vol. 14, No. 8 cartilage cultures to 1, 10 or 100 mg/ml CS at day 7, did not significantly increase PG content by day 14. However, by day 21, 10 and 100 mg/ml CS did enhance PG content as compared to Fn-f treatment alone (P ¼ 0.01 and 0.001, respectively). By day 28, the effects were greater (P < 0.0001 for both). Concentrations of 0.01 and 0.1 mg/ ml were not tested because of the weaker effect of 1 mg/ml. Figure 6 (C) shows that mixtures of the two agents at 1e100 mg/ml when added to nondamaged cartilage did not significantly enhance PG content at any time point as shown in Fig. 6(C) . However, adjustment of Fn-f damaged cartilage cultures to 10 or 100 mg/ml of the mixture at day 7, significantly enhanced PG content by day 14 as compared to Fn-f treatment alone (P < 0.002). At day 21, the effects were still significant for 10 and 100 mg/ml (P < 0.0001 for both). A concentration of 1 mg/ml was also effective (P ¼ 0.003). At day 28, the effects for 1, 10 and 100 mg/ml were still significant (P < 0.0004 for all). Concentrations of 0.01 and 0.1 mg/ml had no significant effect (data not shown).
THE AGENTS DECREASED RELEASE OF MMP-3 IN SERUM CONDITIONS
Conditioned media from the serum cultures tested for blocking activity were probed for MMP-3 at day 7 of the culture period. This time point was chosen since we have shown that release of MMP-3 is maximal during this period 51 as is Fn-f mediated cartilage matrix degradation 54 . The purified thrombin-generated 29-kDa was used for these studies and a Reactive Red 120-agarose capture method was required to isolate the MMP-3 antigen from serum components as described in Materials and methods. MMP-13 expression was not tested because of an apparent failure of the agarose to separate MMP-13 away from serum components. Figure 7 shows that as compared to the serumfree data described earlier, the serum cultures allowed the agents to decrease MMP-3 release into the media to a much greater extent. The separate agents and mixture [ Fig. 7 (A,C,E)] did not enhance MMP-3 except for a slight increase in 0.1 mg/ml CS treated cultures [ Fig. 7(A) ]. When the agents were tested for their ability to block Fn-f, CS strongly blocked even at concentrations as low as 0.1 mg/ml, with a suggestion of lesser blocking as CS concentrations were increased. A concentration of 0.01 was also tested and found not to decrease MMP-3 expression (data not shown).
Similar results were observed with GluNH 2 treatment as well as treatment with the agent mixture (M). Note also the same anomaly we described earlier for GluNH 2 in serum-free conditions and for all three conditions in serum and for CS in panel B. The blocking effect is decreased with higher concentrations of agents. This analysis for MMP-3 release was tested with three different cartilage preparations with similar results.
MIXTURES REVERSED Fn-f MEDIATED PG SYNTHESIS SUPPRESSION
Since GluNH 2 and CS blocked MMP release better than the agent mixture but were relatively inactive in blocking of PG degradation or in promotion of PG restoration, the possibility that the mixture worked through reversal of Fn-f mediated suppression of PG synthesis was investigated. A complication of this analysis is that Fn-f treated cartilage responds to the damage first with suppression of PG synthesis; however, after days 5e7, the PG synthesis rates slowly increase to untreated control levels and above 54, 61, 62 . Thus, the potential effects of the agents on promoting repair can only be tested early in the culture within the first week.
To test effects of the agents on PG synthesis in the absence of Fn-f, cartilage was treated first with the agents alone and the cultured slices then incubated at various times with 35 S sulfate to measure rates of incorporation as a relative measure of PG synthesis. Figure 8(A) shows that the higher concentrations of 10 mg/ml CS appeared to enhance PG synthesis at days 5 and 7 (P < 0.004 for both), while 100 mg/ml significantly enhanced PG synthesis at days 5, 7 and 10 (P < 0.01 for all). The mixture was more effective at later times with 100 mg/ml with significant effects at day 14 (P ¼ 0.004). Concentrations of 0.01, 0.1 and 1 mg/ml had no significant effect (data not shown). The GluNH 2 curves were similar to untreated control data. Next the effect of GluNH 2 on blocking Fn-f mediated PG synthesis suppression was tested. Figure 8(B) shows that the MMP-3 generated Fn-f mixture suppressed PG synthesis by day 2 (P < 0.0001), followed by a reparative response of the cartilage as shown by slowly increasing PG synthesis rates, as we have reported earlier 54 . However, preincubation with 1 mg/ml GluNH 2 for 4 h, followed by addition of Fn-f, reversed Fn-f activity by day 2 (P ¼ 0.0068) with significant reduction through day 5 (P ¼ 0.001) and day 7 (P ¼ 0.01). A concentration of 10 mg/ml was more effective at days 2 and 5 (P < 0.0007 for both) while 100 mg/ml was even more effective at days 2, 5 and 7 (P < 0.0005 for all). By day 10, the differences between Fn-f treatment and the 100 mg/ml GluNH 2 treatment were not significantly different, suggesting that the effects of GluNH 2 are not great enough to cause persistent blocking. Concentrations of 0.01 and 0.1 mg/ml were ineffective (data not shown).
The effects of CS were tested next. Figure 9 (A) shows that CS weakly reversed PG synthesis suppression caused by the Fn-f. Concentrations of 1 mg/ml (P ¼ 0.01), or 10 mg/ ml (P ¼ 0.0001) or 100 mg/ml (P ¼ 0.0002) significantly decreased Fn-f activity at day 2. The effect of 1 mg/ml was lost by day 5, while 10 mg/ml showed a partial effect (P ¼ 0.021) and 100 mg/ml was completely effective at day 5 (P < 0.0001). The 100 mg/ml concentration continued to decrease Fn-f activity through day 10 (P < 0.0001). Concentrations of 0.01 and 0.1 mg/ml were ineffective (data not shown). Fig. 8, panel B . For panel C, cartilage was first damaged with Fn-f for 7 days, the Fn-f removed and then mixtures added at various concentrations at day 7. A control of Fn-f alone (F) is also shown. All values were normalized to untreated controls (100%).
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Osteoarthritis and Cartilage Vol. 14, No. 8 In contrast, Fig. 9(B) shows that mixtures of the agents at 10 or 100 mg/ml were all totally effective in blocking or decreasing Fn-f mediated PG synthesis suppression for up to day 14 (P < 0.0004 at all days). The effects were also greater than untreated control at days 7, 10 and 14 (P < 0.007 at all days). A concentration of 1 mg/ml had a lesser effect for days 2, 5, 7 or 10 (P < 0.006 for all days). A 0.1 mg/ml concentration was indistinguishable from Fn-f treatment (shown), as well as a 0.01 mg/ml concentration (data not shown). The major difference between the agent mixture and the single agents is that the mixture at 10 and 100 mg/ml totally blocked Fn-f mediated PG synthesis suppression at any time point during the culture, while the single agents only had a short term effect.
We next tested whether this blocking effect would also occur in experiments in which the cartilage was damaged first by the Fn-f, the Fn-f removed and the agents added. Figure 9 (C) shows that the Fn-f by itself had significant effects (P < 0.0001). After removal of the Fn-f at day 7 and addition of the mixtures, 1, 10 and 100 mg/ml concentrations reversed the effects of the Fn-f at day 14 (P ¼ 0.01, 0.0007 and 0.0002, respectively). Therefore, the proanabolic activity of the mixture can either occur during the Fn-f mediated damage or after maximal damage has been inflicted.
Discussion
GluNH 2 and CS have been shown to have pain-alleviating effects when taken orally. One basic question has been whether or not these agents also modify damaged cartilage or the progression of damage. Whether or not an agent has disease-modifying effects in OA depends on the demonstration that it can slow progression, with progression measured by a surrogate for structural change. Currently the only accepted surrogate in OA is joint space narrowing (JSN), measured by X-ray 63 . Effects on JSN have been shown for GluNH 2 64, 65 , but until recently had not been shown for CS. Michel et al. 66 recently showed that the same CS (CondroSulf) present in Cosequin and Cosamin DS, when used in long-term treatment, was able to retard radiographic progression in patients with OA of the knee. This same measurement is being made in the ongoing GAIT study using the same source of CS. Thus, our objective was to test whether in our explant model, effects of these agents on protection of the cartilage matrix could be demonstrated. If so, this might suggest similar effects in human subjects. However, it should be noted that we have shown some differences in how Fn-fs damage human cartilage, as compared with bovine cartilage 67 , an observation that might suggest some caution in predicting that the blocking activity of the agent mixture would be as significant on human cartilage as we demonstrate here for bovine cartilage.
With the initiation of this study, there were few observations that demonstrated that these agents were effective in blocking cartilage damage or repairing cartilage in vitro. However, there have been many studies of effects of these agents on cartilage tissue or other cells. Unfortunately, none of these studies were of their effect on the most relevant parameters, such as matrix content. Our objective was to test the effects of the single agents and combinations in a well defined in vitro damage model consisting only of cartilage and Fn-f. While the overall effects must be weighed in the final analysis in human subjects, analysis in a single type of tissue system provides us an opportunity to more clearly observe certain chondrolytic or anti-chondrolytic effects. We utilized a powerful damage system, one that employs Fn-fs that have the capability of removing half of the total PG within 7 days in culture 50e55 . Thus, agents that block Fn-f mediated damage would have to have very potent anti-catabolic or proanabolic activities.
Our initial studies were of serum-free conditions in which anabolic effects mounted by the tissue would have been lesser than in serum because of the absence of growth factors or proteinase inhibitors. These conditions allowed us to study effects mainly on catabolism. We did not observe significant effects of the agents on the kinetics of PG degradation in the presence of Fn-f, although higher concentrations of the mixture appeared to increase the rate of PG release. These data should be treated with caution since other experiments showed that the mixture enhanced PG synthesis and this newly synthesized PG may have been released into the media and contributed to the rates of PG release we measured. This contribution to the rate would have obscured the observation of a blocking effect.
In terms of effects on MMP-3 and -13 release in serumfree conditions, we did observe an early slowing of the release of MMPs, but this effect was mostly lost by 3 days. The temporary nature of this loss might have been due to exhaustion of the added GluNH 2 or CS, since these agents were added only once, at the beginning of the culture. This observation of effects on MMP release is consistent with other observations of the ability of these agents to decrease MMP expression. However, it should be noted that we found effects at mg/ml concentrations, much lower than typically reported. As examples, GluNH 2 at 100 mg/ml suppressed MMP release from normal chondrocytes and synoviocytes but not from OA chondrocytes 68 , GluNH 2 at 1e150 mM suppressed MMP-3 mRNA levels 18e65% in human chondrocytes 22 and GluNH 2 at 2.5 mg/ml decreased MMP-3 protein release 25 . Further, both GluNH 2 and CS were found to decrease MMP gene upregulation in IL-1 challenged bovine cartilage 29 . Our data are also consistent with the reported ability of CS or GluNH 2 to block cytokine activities 27, 28 , since cytokines are involved in Fn-f mediated MMP upregulation 51, 52 .
It should also be noted that we showed that in our serumfree conditions in which no serum contained protease inhibitors would be present, that the agents did not block the activity of the MMPs involved in matrix PG degradation in our Fn-f model, although they have been proposed to act as MMP inhibitors 21,32,34e36 . However, the data in Fig. 2 in which less proMMP-13 but more lower mass MMP-13 was apparent when the culture was treated with the mixture would be consistent with some type of inhibition of proteases involved in proMMP-13 activation.
Subsequent studies with serum present allowed us to study the combined effects of catabolism and anabolism. We found that while the agents singly or in combination did not block Fn-f mediated PG degradation in serum-free conditions, in the presence of serum the agents were more effective likely due to the presence of growth factors in serum which may have facilitated the restoration of PG or the maintenance of steady state levels of PG. The single agents showed weak activity, while the mixture was very active at low concentrations. When tested for reparative activities, a similar trend was observed. Since serum also contains proteinase inhibitors, the serum may have also decreased the proteolytic potential enough such that the enhanced anabolic effects of the test agents were more capable of compensation. Another possible explanation for the differences between our serum-free and serum 802 In order to provide some information on how the agents might be decreasing Fn-f mediated catabolism, the serum cultures were tested for MMP expression. Consistent with our studies in serum-free conditions, the serum conditions also showed an effect on decreasing MMP expression, with the single agents appearing to be more effective than the mixture. Since the mixtures were more effective than the single agents in blocking PG degradation and in restoring PG, the effects on MMP-3 release cannot explain the efficacy of the mixture. It is possible that the agents might be more effective on other proteases involved in cartilage damage, however, we have demonstrated that MMP-3 is largely responsible for PG degradation in our Fn-f culture system 60 . It should also be noted that we measured MMP-3 and -13 in the media. We do not yet know if these agents also blocked MMP-3 transcription.
In terms of PG synthesis, the effects of the agents were first tested in the absence of Fn-f. CS by itself appeared to enhance PG synthesis early in culture but not at later time points, while the mixture was more effective later. GluNH 2 did not show significant effects by itself. When the agents were tested for their ability to reverse Fn-f mediated PG synthesis suppression, the single agents at higher concentrations did have some effect on Fn-f activity. CS at 100 mg/ml did totally block the effect of the Fn-f, while GluNH 2 appeared to be weaker. However, the mixture at 1 mg/ml was nearly as effective as 10 mg/ml CS and the mixture at 1e100 mg/ml totally blocked Fn-f activity. Our observation of the ability of CS to stimulate synthesis of PG is consistent with other reports 12, 13, 17, 33 . Since the mixture which was more effective at blocking PG depleting and restoring PG was also more effective at enhancing PG synthesis than were CS or GluNH 2 , it is possible that a major explanation for efficacy of the mixture is through reversal of Fn-f mediated PG synthesis suppression.
The concept that suppressed MMP release does not lead to blocking of Fn-f mediated damage, while reversal of PG synthesis suppression does is interesting. This supports the notion we published earlier in which we showed that while treatment of both human knee and ankle cartilage with Fn-fs results in enhanced MMP expression and elevated aggrecan degradation neoepitopes, only knee cartilage shows a decrease in PG content 67 . Further, we found that PG synthesis suppression in knee cartilage is more sensitive to Fn-fs than in ankle cartilage 67 . We proposed that the major damaging mechanism of Fn-fs toward human knee cartilage is through suppression of PG synthesis and not through elevated MMPs 67 . In comparison, we have shown that in bovine cartilage, antibodies to MMP-3 slow Fn-f mediated damage 60 . We have also shown that MMP inhibitors block Fn-f mediated damage to bovine cartilage (unpublished). Perhaps these differences are due to species differences as we have discussed 65 . Enhanced MMP activity may be more responsible for Fn-f mediated decreases in cartilage PG content in bovine cartilage than in human knee cartilage. However, the data presented here with bovine cartilage suggest that blocking of MMP-3 or -13 expression by GluNH 2 and CS is not sufficient for blocking of cartilage PG losses. It is also possible that the single agents have secondary negative effects that minimize the beneficial effects of blocking MMP release, while the mixture may have fewer of these side effects.
Our data show that the mixture was much more powerful than the single agents and that concentrations of down to 1 mg/ml of each agent in the mixture could totally block Fn-f mediated PG decreases in cartilage PG content. The effects were partial at 0.1 mg/ml but lost at 0.01 mg/ml. Observation of blocking at such a low concentration may address the preliminary conclusions that the agents by themselves cannot be effective after oral ingestion because of the dilution in the circulatory system. It should be noted that our demonstration of activity in the 0.1e1 mg/ml range is well within the windows reported for measured plasma levels in different species of CS of 5e40 mg/ml 17,38e41 and of GluNH 2 of 2e20 mg/ml 38,42e45 .
Our observations are in accord with other observations 17 and proposals 48, 49 that the mixture is much more effective than the single components. Our data showed that (1) 0.1 mg/ml of the mixture was as effective as 100 mg/ml CS in blocking Fn-f mediated damage; (2) 1 mg/ml of the mixture was more effective than 100 mg/ml GluNH 2 or CS in promoting restoration of PG; and (3) 1 mg/ml of the mixture was more effective than 10 mg/ml CS in blocking Fn-f mediated PG synthesis suppression. Thus, there is at least one order of magnitude difference in the potencies between the single agents and the mixture.
Discussion of the dose dependencies of these agents has to also consider observations that these agents may have an affinity for cartilage 23, 36 . Thus, the serum levels of these agents may greatly underestimate the cartilage bound concentrations. We should also point out that we only preincubated cartilage with these agents for 4 h prior to addition of Fn-f. Since some of our experiments were up to 21 days duration, some concentration into the tissue might have occurred. Thus, we cannot be sure that our final tissue concentration is the same as the initial. This might also explain the trend to show slightly beneficial effects of these agents later in culture.
Regardless of the mechanism, this work is among the first to show the effects of these agents in an explant cartilage degeneration model in which a far downstream correlate of cartilage damage, PG depletion and restoration were studied. While the enhanced PG synthesis is consistent with cartilage repair, it should be noted that increased PG synthesis also occurs in early OA as well as during conditions in which the Fn-f causes minimal damage to cartilage 54 . Thus, the increased PG synthesis we observed may not actually lead to stable repair. Further studies will be needed to confirm stable restoration of PG and other matrix components, restoration of structural integrity of the matrix and cessation or decreases of enhanced catabolic pathways. Our observations of the greater effects of the mixtures, suggest that single formulations may be less effective as nutraceutical compounds. Lastly, the concentrations of agents we found to be effective are actually lower than the concentrations measured in plasma of different species after oral ingestion of the agents 17,38e45 , further suggesting that these compounds might be capable of altering chondrocyte metabolism even with dilution into the circulatory system.
